Clinical trials of drugs intended to treat secondary hypogonadism should be premised upon symptom-based endpoints and fertility measures, an FDA advisory committee said Dec. 6.
In a series of votes on different treatment scenarios and patient populations, members of the Bone, Reproductive and Urologic Drugs Advisory Committee made clear their preference for endpoints that are more clinically meaningful than merely looking at increases in testosterone or sperm concentration in patients with low testosterone levels that are not
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?